# A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

> **NCT05586789** · PHASE3 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 220 (actual)

## Conditions studied

- Anxiety
- Neurasthenia
- Adjustment Disorders

## Interventions

- **DRUG:** Ranquilon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05586789
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2022-11-22
- **Final completion:** 2023-01-03
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05586789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05586789, "A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05586789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*